MEAN ABSOLUTE EASI AND PRURITUS ACHIEVED BY LEBRIKIZUMAB OVER 16 WEEKS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Recommended Citation
Vestergaard C, Thaci D, Puig L, Papp KA, Stein Gold LF, Peñas PF, Huang Y, Dossenbach M, Falques M, Agell H, Gaarn Du Jardin K. MEAN ABSOLUTE EASI AND PRURITUS ACHIEVED BY LEBRIKIZUMAB OVER 16 WEEKS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. Acta Derm Venereol 2025; 105:37.
Document Type
Conference Proceeding
Publication Date
5-6-2025
Publication Title
Acta Derm Venereol
Abstract
Purpose: Lebrikizumab (LEB) is a monoclonal antibody that binds with high-affinity to interleukin-13, blocking its downstream effects. Efficacy based on absolute values is clini-cally relevant as they report remaining disease. Here, we present EASI and pruritus-NRS least square mean scores in the overall population treated with LEB 250mg Q2W monotherapy vs pla-cebo at baseline and W16 (ADvocate1 [ADv1, NCT04146363 trials (pooled-data).Methods: Adults (≥ 18 years) and adolescents (12-<18 years,≥ 40 kg) were randomized 2:1 to LEB monotherapy (N = 564): placebo (PBO; N = 287) for 16W. LEB was given as a 500mg loading dose at baseline and W2, followed by 250mg LEB Q2W. Eligible patients had moderate-to-severe AD (EASI≥ 16, IGA≥ 3, body surface area ≥ 10% AD involvement). Efficacy analyses were conducted in the modified intention-to-treat population, using a mixed model of repeated measures based on observed cases up to intercurrent events.Results: In the ADv1&2 population, LEB Q2W showed significant improvement from baseline to W16 in least square mean scores of EASI (29.3 to 7.8) vs PBO (30.0 to 18.4) (p < 0.001 at W16) and pruritus-NRS (7.2 to 3.5) vs PBO (7.2 to 5.7) (p < 0.001 at W16), respectively.Conclusions: LEB Q2W significantly improved EASI and pru-ritus vs placebo and decreased disease severity as measured by EASI from severe to moderate and pruritus from moderate to mild at W16.
Volume
105
First Page
37
